Navigating Treatment Selection in Hypercortisolism

In this episode, ‘Navigating Treatment Selection in Hypercortisolism,’ the expert endocrinologists explore available treatment options for hypercortisolism and discuss how clinicians individualize therapy based on disease etiology, severity, comorbidities, and long-term treatment goals. The panelists explain that while surgery remains the preferred approach when a removable source of cortisol excess is identified, medical therapy plays an important role for patients who are not immediate surgical candidates, require preoperative optimization, or need chronic disease management.

The panel of experts reviews several therapeutic approaches, including cortisol synthesis inhibitors, glucocorticoid receptor antagonism, pituitary-directed therapies, and other strategies used in more severe presentations. They discuss how cortisol synthesis inhibitors reduce cortisol production, while glucocorticoid receptor antagonists block cortisol activity at the receptor level. Faculty members also highlight practical differences among available agents, including considerations related to potency, tolerability, adverse effects, and the need for either titrate-to-goal or block-and-replace strategies.

Throughout the conversation, the panel emphasizes that treatment selection should be individualized. They discuss how the severity and cause of hypercortisolism influence the urgency and type of therapy selected, with more severe cases potentially requiring rapid cortisol control. The experts also examine how patient-specific factors, such as uncontrolled diabetes, hypertension, liver disease, pregnancy, and risk of medication-related adverse effects, may guide therapeutic decision-making. The discussion further highlights the importance of considering long-term management because many patients may require ongoing or lifelong therapy. By comparing mechanisms of action and clinical considerations across treatment options, the panel provides a practical framework for selecting therapy in patients with hypercortisolism.

The next episode in this series, ‘Emerging Clinical Evidence and Cardiometabolic Outcomes in Hypercortisolism,’ features the panelists discussing recent clinical trial and real-world evidence evaluating available therapies for hypercortisolism. The expert faculty explore treatment effects on cortisol control, blood pressure, glycemic outcomes, and practical considerations for optimizing long-term disease management.